{"organizations": [], "uuid": "d7a79111e99657bb01bfb92a023f6d10767a6ee5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180124.html", "section_title": "Archive News &amp; Video for Wednesday, 24 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/novartis-results/novartis-beats-analyst-forecasts-predicts-2018-growth-on-new-drugs-idUSL8N1PI6Z6", "country": "US", "domain_rank": 408, "title": "Novartis beats analyst forecasts, predicts 2018 growth on new drugs", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-24T14:20:00.000+02:00", "replies_count": 0, "uuid": "d7a79111e99657bb01bfb92a023f6d10767a6ee5"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/novartis-results/novartis-beats-analyst-forecasts-predicts-2018-growth-on-new-drugs-idUSL8N1PI6Z6", "ord_in_thread": 0, "title": "Novartis beats analyst forecasts, predicts 2018 growth on new drugs", "locations": [], "entities": {"persons": [{"name": "john revill", "sentiment": "none"}, {"name": "john miller", "sentiment": "none"}], "locations": [{"name": "basel", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "novartis", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "BASEL, Jan 24 (Reuters) - Swiss drugmaker Novartis on Wednesday forecast 2018 operating profit would grow faster than sales as revenue from drugs including its latest blockbuster Cosentyx accelerates and the company exits a period when patent losses dented results.\nCore net income in the fourth quarter of 2017 rose 6 percent to $2.82 billion, Novartis said in a statement, compared to the $2.751 billion average forecast in a Reuters poll. Fourth-quarter sales rose to $12.9 billion, compared to the Reuters poll average of $12.62 billion.\nThe company said 2018 sales would grow at a low-to-mid single digit percentage rate, with core operating profit rising in the mid-to-high single digit percentage range. (Reporting by John Miller, editing by John Revill)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-24T14:20:00.000+02:00", "crawled": "2018-01-25T13:18:49.006+02:00", "highlightTitle": ""}